4.7 Article

Differential interaction of HIV-1 integrase and JPO2 with the C terminus of LEDGF/p75

Journal

JOURNAL OF MOLECULAR BIOLOGY
Volume 372, Issue 2, Pages 407-421

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jmb.2007.06.090

Keywords

JPO2; LEDGF/p75; HIV-1; integrase; D366A

Ask authors/readers for more resources

The transcriptional co-activator lens epithelium-derived growth factor (LEDGF) has been shown to protect cells against enviromnental stress. The protein has been implicated in auto-immunity and cancer, and is present in cells as the p52 or p75 splice variant. Recently, LEDGF/p75, but not p52, was identified as the prominent interaction partner of human immunodeficiency virus type 1 (HIV-1) integrase. This interaction of HIV-1 integrase with the C-terminal integrase-bin ding domain of LEDGF/p75 is crucial for HIV-1 replication. To gain insight into the cell biology of LEDGF/p75, we were interested in identifying cellular binding partners of its C-terminal domain. By yeast-two-hybrid screening with a CEMC7 cDNA-library, we were able to identify JP02 as a binding partner of the C-terminal part of LEDGF/p75. The specific interaction between JP02 and LEDGF/p75 was verified by pull-down, AlphaScreen, and co-immunoprecipitation. Competition assays using recombinant proteins show a mutually exclusive binding of either JP02 or HIV-1 integrase to LEDGF/p75. However, differing mechanisms of binding were suggested by continuing interaction of JP02 with some LEDGF/p75 mutants (I365A, D366A, F406A) that are totally defective for interaction with HIV-1 integrase. This finding is of significance for the development of specific inhibitors targeting only the interaction between LEDGF/p75 and HIV-1 integrase, without disturbing interaction with other cellular factors. Over-expression of JP02 resulted in a modest but reproducible inhibition of HIV-1 replication, consistent with competition between integrase and JP02 for binding to LEDGF/p75. Furthermore, JP02 over-expression activated transcription from the HIV-1 LTR. (C) 2007 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available